World Immunotherapy Congress - Agenda Day 3

 

World Immunotherapy Congress 2018, Day 3

08:00 Registration Opens

08:50 Conference doors open

Keynote plenary - World leading research

Dr M. Anthony Moody
09:05

Hiding in plain sight: Fc-receptor variation and comparison of human and animal models

  • Human Fc-receptor variation can affect response to vaccines and passive immunotherapy
  • Animal model testing of therapeutics that require Fc-receptor dependent interactions could give different results than human studies
  • Fc-receptor diversity in humans appears to be low but significant, while in non-human primates, diversity appears to be high and of unclear significance
Heinz Läubli
09:30

Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo resulted in increased anti-cancer immunity

  • Changes of glycans in the tumor microenvironment
  • Upregulation of sialoglycans increase density of ligands for Siglec receptor
  • Siglec receptors are new immune checkpoints upregulated on tumor-infiltrating T cells
  • Siglec-sialoglycan interactions can be targeted to improve anti-cancer immunity
William Jia
09:55

Strong anti-tumor immunity synergistically activated by an oncolytic virus VG161 armed with multiple immune stimulating genes

  • VG161: An Investigational New Drug (IND) enabled oncolytic virus (OV) armed with multiple anti-tumor regulatory factors
  • Strong anti-tumor effect demonstrated in multiple animal tumor models
  • Lasting anti-tumor immunity by VG161 in comparison with non-armed OV

10:20 Networking Break

Cancer vaccines

Safety and efficacy

Chaired by Eric Halioua, President and Chief Executive Officer, PDC*line Pharma

Chaired by Saad J. Kenderian, Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine

Immunotherapy - Cancer vaccines
11:40

PDC*line Pharma semi-allogeneic cancer vaccine: how abortive allogeneic immune response can prime and boost the induction of specific anti-tumor T cells

  • PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
  • PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
  • The technology can be applied for any type of cancer
Immunotherapy - Safety and efficacy
11:40

Tolerogenic nanoparticles to mitigate immunogenicity and improve the efficacy of immunotoxins for cancer therapy

  • The development of anti-drug antibodies (ADAs) can compromise the efficacy and safety of biologic therapies
  • Recombinant immunotoxins are potent but highly immunogenic anti-cancer agents
  • We have partnered with the National Cancer Institute to demonstrate that synthetic vaccine particles nanoparticles containing rapamycin (SVP-Rapamycin) effectively mitigate ADAs against LMB-100, a mesothelin-targeted immunotoxin, and enables robust anti-tumor responses in preclinical models
  • The combination of LMB-100 and SVP-Rapamycin is currently in clinical trials for the treatment of patients with mesothelioma
Immunotherapy - Cancer vaccines
12:05

Cell penetrating peptides and TLR peptide agonist: the swiss army knife of cancer vaccines

  • Therapeutics cancer vaccines
  • Chimeric proteins
  • Multi-antigenic T cells immunity responsive
Immunotherapy - Cancer vaccines
12:30

Accelerate your immunotherapy target discovery using immune repertoire sequencing

  • Key challenges in characterizing the immune repertoire
  • Using the ImmunoGenomiX (IGX) platform to accurately analyze the immune repertoire
  • Sequencing the immune repertoire to develop new biomarkers
  • Use cases in oncology and beyond
Nicola Bonzanni, Chief Scientific Officer, ENPICOM
Immunotherapy - Safety and efficacy
12:30

Risk profiling of peptide targets for immunotherapeutic discovery

  • Integrating multi-omics data and predictive algorithms.
  • Assessing off-target effects for immunotherapies provides clearer picture of risk landscape.
  • Direct and optimise screening to ensure risks are covered.
  • Systematic Identification of high priority targets using advanced predictive modelling.

12:55 Networking Lunch

Closing plenary – biomarkers and precision medicine for immunotherapy

Chaired by Thomas Hach, Director, Healthcare Systems, Novartis

14:00

Patient selection strategies for making precision medicine a reality in immuno-oncology

Thomas Hach
14:20

The future of precision medicine

  • Oncology and genomics: halfway there
  • Immunology and more Omics: we’re just starting
  • The future: complexity simplified, research put into practice, digital put into action
Tim Fugmann
14:40

The HLA peptidome as a novel biomarker to predict response to immunotherapy

  • Antigen-specific T cells can mediate significant tumour cell killing
  • Immunotherapy can increase the number and activity of TILs
  • Increasing our knowledge of tumour-specific (neo-) antigens may facilitate therapeutic strategies
  • Peptides presented on HLA complexes predict response to therapy
15:00

Response and resistance in CAR-T therapy

15:20

Chairman's closing remarks

15:25

Closing remarks from Terrapinn

15:30 End of Congress

last published: 15/Oct/18 13:05 GMT

 

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates